Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
Authors:
- Rajesh PahwaRPRajesh Pahwa
- William C. KollerWKWilliam C. Koller
- Richard M. TroschRTRichard M. Trosch
- James H. SherryJSJames H. Sherry
- 1 July 2007
- journal article
- research article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 258 (1-2) , 137-143
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Literature reviewNeurology, 2004
- Subcutaneous ApomorphineDrugs & Aging, 2004
- Prevention and treatment of motor fluctuationsParkinsonism & Related Disorders, 2003
- Levodopa-Induced Response Fluctuations in Patients with Parkinson???s DiseaseCNS Drugs, 2003
- A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State EventsArchives of Neurology, 2001
- Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literatureMovement Disorders, 2001
- Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa1999
- Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Unified Parkinson's disease rating scale characteristics and structureMovement Disorders, 1994
- ParkinsonismNeurology, 1967